FiercePharma's Carly Helfand and FierceBiotech's Damian Garde discuss a rough day for Valeant Pharmaceuticals and Biogen, plus the changing in winds in biotech venture capital.
Download the episode on iTunes or Stitcher, or listen below--and be sure to subscribe. Let us know what you think by dropping a line to [email protected].